Second Sight Reports 16 Argus II Implants in Q1-2018

May 11, 2018: By Jon Swedien

Second SightSecond Sight announced May 10 that surgeons implanted 16 Argus II Retinal Prosthesis Systems worldwide in Q1-2018, up from 14 implants during Q1-2017.

Net sales for the quarter totaled $1 million, Second Sight reported.

The Sylmar, California, company also reported that it completed a $10 million private placement on May 3 of 6.75 million shares of common stock priced at $1.48—the closing price on that date—with entities beneficially owned by Gregg Williams, Second Sight’s board chair.

Second Sight appointed Williams board chair in April.

The funding is expected to give Second Sight the financing its needs to achieve key commercial and developmental milestones for its Argus II and Orion programs, the company said.

The Argus II converts images captured by a miniature video camera mounted on a patient’s glasses into a series of small electrical pulses. It is designed to induce visual perception in individuals with severe to profound retinitis pigmentosa.

The Orion Cortical Visual Prosthesis System works similarly to the Argus II, though it is implanted on the surface of the visual cortex.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023